Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:16114285rdf:typepubmed:Citationlld:pubmed
pubmed-article:16114285lifeskim:mentionsumls-concept:C0027793lld:lifeskim
pubmed-article:16114285lifeskim:mentionsumls-concept:C0282151lld:lifeskim
pubmed-article:16114285lifeskim:mentionsumls-concept:C0441889lld:lifeskim
pubmed-article:16114285lifeskim:mentionsumls-concept:C2698651lld:lifeskim
pubmed-article:16114285pubmed:issue31lld:pubmed
pubmed-article:16114285pubmed:dateCreated2005-8-23lld:pubmed
pubmed-article:16114285pubmed:abstractTextDopaminergic neurotransmission affects an individual's subjective experience. Individuals with lower baseline dopamine function are at an increased risk for dysphoric responses during antipsychotic therapy with dopaminergic-blocking drugs. Reaching an optimal dopamine D2-receptor occupancy is therefore relevant for the quality of life. Doses of antipsychotic drugs administered to such individuals often need to be lower than the commonly used levels, as these may induce drowsiness and lack of energy.lld:pubmed
pubmed-article:16114285pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16114285pubmed:languagedutlld:pubmed
pubmed-article:16114285pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16114285pubmed:citationSubsetIMlld:pubmed
pubmed-article:16114285pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16114285pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16114285pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16114285pubmed:statusMEDLINElld:pubmed
pubmed-article:16114285pubmed:monthJullld:pubmed
pubmed-article:16114285pubmed:issn0028-2162lld:pubmed
pubmed-article:16114285pubmed:authorpubmed-author:de HaasCClld:pubmed
pubmed-article:16114285pubmed:issnTypePrintlld:pubmed
pubmed-article:16114285pubmed:day30lld:pubmed
pubmed-article:16114285pubmed:volume149lld:pubmed
pubmed-article:16114285pubmed:ownerNLMlld:pubmed
pubmed-article:16114285pubmed:authorsCompleteYlld:pubmed
pubmed-article:16114285pubmed:pagination1721-2lld:pubmed
pubmed-article:16114285pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:16114285pubmed:meshHeadingpubmed-meshheading:16114285...lld:pubmed
pubmed-article:16114285pubmed:meshHeadingpubmed-meshheading:16114285...lld:pubmed
pubmed-article:16114285pubmed:meshHeadingpubmed-meshheading:16114285...lld:pubmed
pubmed-article:16114285pubmed:meshHeadingpubmed-meshheading:16114285...lld:pubmed
pubmed-article:16114285pubmed:meshHeadingpubmed-meshheading:16114285...lld:pubmed
pubmed-article:16114285pubmed:meshHeadingpubmed-meshheading:16114285...lld:pubmed
pubmed-article:16114285pubmed:meshHeadingpubmed-meshheading:16114285...lld:pubmed
pubmed-article:16114285pubmed:meshHeadingpubmed-meshheading:16114285...lld:pubmed
pubmed-article:16114285pubmed:meshHeadingpubmed-meshheading:16114285...lld:pubmed
pubmed-article:16114285pubmed:meshHeadingpubmed-meshheading:16114285...lld:pubmed
pubmed-article:16114285pubmed:year2005lld:pubmed
pubmed-article:16114285pubmed:articleTitle[The optimal level of dopaminergic neurotransmission].lld:pubmed
pubmed-article:16114285pubmed:affiliationAcademisch Medisch Centrum/Universiteit van Amsterdam, locatie MFO Psychiatrie/AMC De Meren, Adolescentenkliniek, Tafelbergweg 25, 1105 BC Amsterdam. l.dehaan@amc.uva.nllld:pubmed
pubmed-article:16114285pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:16114285pubmed:publicationTypeEnglish Abstractlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:16114285lld:pubmed